Under the new agreement, HistoRx will provide Lilly researchers broad access to the Aqua technology for tissue biomarker analysis, and HistoRx will develop customized Aqua analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.
The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx Aqua technology to help advance select Lilly pharmaceutical development programs.
Rana Gupta, CEO of HistoRx, said: “By revealing stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome, we expect this ongoing partnership to continue providing a substantial boost to Lilly’s drug research and development programs.”